PPD - AzurRx Biopharma engages PPD to manage niclosamide clinical trial
AzurRx BioPharma ([[AZRX]] -7.8%) has entered into an agreement with global contract research organization PPD <
> for its planned Phase 1b/2a clinical trial evaluating proprietary formulations of micronized niclosamide for grade 1 colitis and diarrhea in oncology patients receiving treatment with immune checkpoint inhibitors ((ICIs)).Under the terms of the agreement, PPD will manage the Phase 1b/2a clinical trial using both oral immediate-release tablet and topical rectal enema foam formulations of micronized oral niclosamide, also known as FW-420.AzurRx expects to initiate the trial during the second quarter of 2021.PPD is also managing AzurRx’s Phase 2 trial to investigate niclosamide as a treatment for COVID-19-related gastrointestinal infections, planned for the second quarter of 2021.
For further details see:
AzurRx Biopharma engages PPD to manage niclosamide clinical trial